# TDM Guided Early Optimization of ADAL in Crohn's Disease

> **NCT03261102** · NA · ACTIVE_NOT_RECRUITING · sponsor: **waqqas.afif** · enrollment: 200 (estimated)

## Conditions studied

- Crohn Disease
- Drug Monitoring
- Inflammatory Bowel Diseases

## Interventions

- **BIOLOGICAL:** Adalimumab

## Key facts

- **NCT ID:** NCT03261102
- **Lead sponsor:** waqqas.afif
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2017-01-17
- **Primary completion:** 2025-01-15
- **Final completion:** 2025-06-01
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2025-05-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03261102

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03261102, "TDM Guided Early Optimization of ADAL in Crohn's Disease". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03261102. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*